Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC

A pair of global China players kicked off the New Year by selling stakes in entities to bring in nine-digit sums.  

On the heels of Wuxi Apptec Co. Ltd. (Shanghai:603259; HKEX:2359) offloading cell and gene therapy operations in the U.K. and U.S., Wuxi Biologics Inc. (HKEX:2269) said Monday in a regulatory filing that it is selling its Wuxi Vaccines Ireland unit to Merck & Co. Inc. (NYSE:MRK) for $500 million. ...